Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887392 | 0.89 | CHRM1 (0.51) | CHRM1ENPP2MAPTALDH1A1HTT | |
| SCHEMBL4887369 | 0.89 | CHRM1 (0.51) | CHRM1ENPP2MAPTALDH1A1HTT | |
| SCHEMBL508657 | 0.88 | CHRM1 (0.62) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL508656 | 0.88 | CHRM1 (0.62) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4884286 | 0.83 | CHRM1 (0.71) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4884274 | 0.83 | CHRM1 (0.71) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4891561 | 0.81 | CHRM1 (0.61) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4882765 | 0.81 | CHRM1 (0.73) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4882751 | 0.81 | CHRM1 (0.73) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| Pretomanid SCHEMBL14004006 | 0.81 | CHRM1 (1.00) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | NQO2, NQO1, MT-ND2 | CHRM1 1746/4885PTGS1 745/4885SLC6A2 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.